Amoéba announces that the US EPA has approved the use of the lysate of Willaertia magna C2c Maky as an active substance for use in plant protection.

Amoéba announces the publication of its 2022 field trial results, a record year for the number and performance of field trials.

Amoéba announces that it will not pursue the application for its living amoeba-based biocide in Canada.

Amoéba announces the publication of a scientific article concerning the efficacy of its biocontrol products to fight potato late blight.

Amoéba informs that the US EPA approves tolerance exemption for the biocontrol active substance on foodstuffs.

Amoéba announces today that it has published its Interim Financial Report for 2022.

Amoeba announces its half-year results for 2022

Amoéba informs that the United States Environmental Protection Agency (US EPA) has made a positive pre-decisional determination following its assessment of the application dossier for the use of the Lysate of Willaertia magna C2c Maky as a biocontrol active ingredient (biopesticide) in agriculture.

Amoéba announces the issuance of the sixth tranche of 60 bonds convertible into shares.

Amoéba informs that the US EPA has made a positive pre-decisional determination for the use of Amoéba’s biocide in closed cooling systems.

Amoéba announces the issuance of the fifth tranche of 60 bonds convertible into shares as part of its new bond financing with incentive program with Nice & Green S.A.

Amoeba announces that the US EPA, in charge of the evaluation of the biocide and biocontrol applications in the United States, has requested an extension of the assessment period : the conclusions should now be available in the second half of 2022.

Amoéba announces the availability of preparatory documents for the General Assembly of May 24, 2022

Amoeba announces that the Maltese authority recommends the non-approval of the biocidal active substance for the European territory

Amoéba announces that AGES, in charge of the application for approval of the biocontrol active substance “Lysate of Willaertia magna C2c Maky”, recommends its approval for use in plant protection on the European territory.

Amoéba announces that the 2021 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers AMF) on April 12, 2022.

Amoéba announces having exercised the suspension option relating to the issuance of the 5th tranche of OCAs, initially scheduled for April 5, 2022.

Amoéba announces a report of the conclusion of the evaluation of the European biocide and biocontrol dossiers.

Amoeba confirms its biocontrol’s effectiveness against major cereal diseases

Amoéba announces the results of the field trials 3rd campaign on grapes

Malta commits to finalize the report in the 4th quarter of 2021

Philippe Dujardin replaces Pascal Reber as independent director

Availability of the preparatory documents for the General meeting of 27 may 2021

Amoéba provides shareholders with preparatory documents

Amoeba continues testing its biocontrol product in 2021

Amoéba extends to the U.S.A. the testing of its biocontrol

Amoéba has appointed Pierre Morgon as censor.

Signature of a Letter of Intent (LOI) with PHILAGRO France

in Switzerland with Stähler for its vine Bioncontrol product.